Literature DB >> 22001233

Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis.

Eric A Schwartz1, Peter D Reaven.   

Abstract

Epidemiological and interventional studies have implicated elevated triglyceride-rich lipoprotein (TGRL) levels as a risk factor for cardiovascular disease and vascular inflammation, though the results have not been entirely consistent. This appears particularly relevant in model systems where the lipolysis occurs in the setting of established inflammation (e.g., in pre-existing atherosclerotic plaques), rather than in the tissue capillary beds where lipolysis normally occurs. Two main mechanisms seem to link TGRL lipolysis to vascular inflammation. First, lipolysis of TGRL leaves behind partially lipolyzed remnant particles which are better able to enter the vessel wall than nascent TGRL, have a rate of egress substantially lower than their rate of entry, and contain 5-20 times more cholesterol per particle than LDL. Furthermore, remnants do not require oxidation or other modifications to be phagocytized by macrophages, enhancing foam cell formation. Second, saturated fatty acids and oxidized phospholipids released by lipolysis induce inflammation by activating Toll-like receptors of the innate immune system, via oxidative stress, or by greatly amplifying existing pro-inflammatory signals (caused by subclinical endotoxemia) via mitogen-activated protein kinases. However, n-3 and unbound n-9 unsaturated fatty acids released by lipolysis have anti-inflammatory effects. Thus, the contribution of TGRL lipolysis to inflammation likely depends less on the TGRL concentration than on the balance between pro- and anti-inflammatory factors, and on the setting in which the lipolysis occurs. In the setting of the typical "Western" diet, enriched in saturated and oxidized fatty acids and excessive in size, this balance is likely to be tilted towards increased vascular inflammation and atherosclerosis. This article is part of a Special Issue entitled Triglyceride Metabolism and Disease. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001233     DOI: 10.1016/j.bbalip.2011.09.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  31 in total

1.  Regulating intestinal function to reduce atherogenic lipoproteins.

Authors:  M Mahmood Hussain; Tung Ming Leung; Liye Zhou; Sarah Abu-Merhi
Journal:  Clin Lipidol       Date:  2013-08-01

Review 2.  Use of Primary Macrophages for Searching Novel Immunocorrectors.

Authors:  Nikita G Nikiforov; Natalia V Elizova; Michael Bukrinsky; Larisa Dubrovsky; Vsevolod J Makeev; Yoshiyuki Wakabayashi; Poching Liu; Kathy K Foxx; Howard S Kruth; Xueting Jin; Emile R Zakiev; Alexander N Orekhov
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

3.  Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans.

Authors:  Hans L Mooij; Sophie J Bernelot Moens; Philip L S M Gordts; Kristin I Stanford; Erin M Foley; Marjolein A W van den Boogert; Julia J Witjes; H Carlijne Hassing; Michael W Tanck; Michiel A J van de Sande; J Han Levels; John J P Kastelein; Erik S G Stroes; Geesje M Dallinga-Thie; Jeff D Esko; Max Nieuwdorp
Journal:  J Lipid Res       Date:  2015-01-07       Impact factor: 5.922

4.  Angiopoietin-like 4: A double-edged sword in atherosclerosis and ischemic stroke?

Authors:  Liang Xu; Zhen-Ni Guo; Yi Yang; Jun Xu; Sherrefa R Burchell; Jiping Tang; Jianmin Zhang; Jing Xu; John H Zhang
Journal:  Exp Neurol       Date:  2015-05-29       Impact factor: 5.330

Review 5.  Role of lipotoxicity in endothelial dysfunction.

Authors:  Jeong-a Kim; Monica Montagnani; Sruti Chandrasekran; Michael J Quon
Journal:  Heart Fail Clin       Date:  2012-08-10       Impact factor: 3.179

Review 6.  2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.

Authors:  Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-15       Impact factor: 8.311

Review 7.  Metabolomics in diabetic complications.

Authors:  Laura A Filla; James L Edwards
Journal:  Mol Biosyst       Date:  2016-02-19

8.  EPA and DHA exposure alters the inflammatory response but not the surface expression of Toll-like receptor 4 in macrophages.

Authors:  Kaori L Honda; Stefania Lamon-Fava; Nirupa R Matthan; Dayong Wu; Alice H Lichtenstein
Journal:  Lipids       Date:  2014-11-19       Impact factor: 1.880

9.  The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.

Authors:  Muhammed Süleymanoğlu; İbrahim Rencüzoğulları; Yavuz Karabağ; Metin Çağdaş; Mahmut Yesin; Ayça Gümüşdağ; Murat Çap; Murat Gök; İbrahim Yıldız
Journal:  Int J Cardiovasc Imaging       Date:  2020-01-09       Impact factor: 2.357

Review 10.  Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors:  Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.